In the landmark STEP 1 trial, published in the New England Journal of Medicine , 1,961 adults with a BMI of 30 or greater (or 27 or greater with comorbidities) were randomized to receive once-weekly subcutaneous semaglutide 2.4 mg or a placebo, alongside a lifestyle intervention
In: Feingold KR, Anawalt B, Blackman MR, et al, eds
Gerber Why Read It
Prof Adam Taylor, from Lancaster University, said potential benefits in pre-clinical studies such as those in animals and cells do not necessarily mean a peptide is beneficial for humans
When patients are unable to get a GLP-1 drug, whether its to treat diabetes or obesity, they may look to alternative sources for fulfillment
Initially, such drugs were approved solely to manage diabetes